South Korea-based health tech startup Noul Co. has announced that its European subsidiary (noul GmbH) has become an official member of the Swiss Malaria Group, a Swiss public, private, academic & civil society leadership network for a malaria-free world.

The recognition of innovation in the malaria diagnostic solution, miLab MAL played a major role in Noul becoming an official member of the Swiss Malaria Group. Through this membership, Noul will have a voice in the decision-making process towards developing healthcare policies to eradicate global malaria and will strengthen its global cooperation with other group members (Global Fund, FIND, MMV, Swiss TPH, Terre des Hommes, global pharmaceutical companies, and other civil society organisations) to consolidate its leadership in the field of malaria diagnosis.

As Noul's malaria diagnostic solution, miLab MAL was introduced as 'an innovative product that will enter scale-up level' in Unitaid's 2022 Annual Report, it is getting attention from the international community as an innovative malaria diagnostic solution that overcomes the limitation of rapid diagnostic testing and manual microscopic diagnosis.

According to the results of a clinical study of a total of 1,649 patients in Ethiopia and Ghana, unveiled in October 2023 at the American Academy of Tropical Medicine and Hygiene (ASTMH), miLab MAL showed significantly higher sensitivity and specificity in diagnosis of P. falciparum and P. vivax malaria compared to field microscopy test. It also showed high applicability in diagnosing parasites with the pfhrp2/3 deletions.